We are live on ! Find out more
AC

Aristides Capital Portfolio holdings

AUM $514M
1-Year Est. Return 29.58%
This Fund
S&P 500
This Quarter Est. Return
+11.36%
1 Year Est. Return
+29.58%
3 Year Est. Return
+126.23%
5 Year Est. Return
+149.34%
10 Year Est. Return
AUM
$488M
AUM Growth
+$166M
Cap. Flow
+$64.2M
Cap. Flow %
13.14%
Top 10 Hldgs %
49.86%
Holding
365
New
127
Increased
137
Reduced
21
Closed
62

Sector Composition

Rank Sector Weight
1 Miscellaneous 59.07%
2 Technology 10.51%
3 Industrials 6.26%
4 Financials 6.12%
5 Consumer Discretionary 5.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EVH icon
226
Evolent Health
EVH
$423M
$209K 0.04%
+18,600
New +$327K
DNA icon
227
Ginkgo Bioworks
DNA
$475M
$209K 0.04%
+21,300
New +$183K
SBLK icon
228
Star Bulk Carriers
SBLK
$3.58B
$208K 0.04%
+13,900
New +$258K
PLAY icon
229
Dave & Buster's
PLAY
$239M
$207K 0.04%
+7,100
New +$247K
PRME icon
230
Prime Medicine
PRME
$544M
$206K 0.04%
+70,500
New +$247K
FOXF icon
231
Fox Factory Holding Corp
FOXF
$812M
$206K 0.04%
+6,800
New +$234K
IMTX icon
232
Immatics
IMTX
$1.32B
$205K 0.04%
+28,900
New +$248K
KSS icon
233
Kohl's
KSS
$1.87B
$205K 0.04%
+14,600
New +$252K
SITC icon
234
SITE Centers
SITC
$153M
$205K 0.04%
+13,400
New +$216K
PHAT icon
235
Phathom Pharmaceuticals
PHAT
$622M
$205K 0.04%
+25,200
New +$312K
BYND icon
236
Beyond Meat
BYND
$188M
$205K 0.04%
+1,814
New +$289K
ACMR icon
237
ACM Research
ACMR
$4.51B
$204K 0.04%
+13,500
New +$244K
HDSN
238
Hudson Technologies
HDSN
$219M
$204K 0.04%
+36,500
New +$241K
CLDX icon
239
Celldex Therapeutics
CLDX
$3.04B
$202K 0.04%
+8,000
New +$217K
ALEC icon
240
Alector
ALEC
$215M
$201K 0.04%
+106,600
New +$401K
ATKR icon
241
Atkore
ATKR
$3.19B
$200K 0.04%
+2,400
New +$212K
MYGN icon
242
Myriad Genetics
MYGN
$369M
$199K 0.04%
+14,500
New +$268K
TNGX icon
243
Tango Therapeutics
TNGX
$3.94B
$199K 0.04%
+64,300
New +$299K
HPP
244
Hudson Pacific Properties
HPP
$620M
$197K 0.04%
+9,300
New +$254K
SNDX icon
245
Syndax Pharmaceuticals
SNDX
$1.54B
$197K 0.04%
+14,900
New +$255K
PYXS icon
246
Pyxis Oncology
PYXS
$279M
$193K 0.04%
+124,000
New +$358K
LXEO icon
247
Lexeo Therapeutics
LXEO
$341M
$193K 0.04%
+29,285
New +$231K
LESL icon
248
Leslie's
LESL
$5M
$192K 0.04%
+4,295
New +$228K
PAGS icon
249
PagSeguro Digital
PAGS
$2.61B
$191K 0.04%
+30,500
New +$234K
OLMA icon
250
Olema Pharmaceuticals
OLMA
$851M
$189K 0.04%
+32,500
New +$325K

Similar funds

Aristides Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Aristides Capital held 365 positions worth $488M, up 52% from $322M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Aristides Capital deployed $64.2M of net new capital in Q4 2024, opening 127 new positions and adding to 137 existing holdings. Its largest new stake was iShares Core S&P Small-Cap ETF: 60,000 shares worth $6.91M.

By sector, the portfolio is most concentrated in Miscellaneous at 59% of assets, up from 50% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $8.83M trimmed.

  • Aristides Capital's largest Q4 2024 buy was iShares Core S&P Small-Cap ETF: 60,000 shares worth $6.91M.
  • Aristides Capital added most to iShares Bitcoin Trust in Q4 2024, an estimated $19.4M increase.
  • Aristides Capital's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $8.83M.
  • Aristides Capital fully exited Tortoise Midstream Energy Fund, Inc. Common Stock in Q4 2024, selling an estimated $5.01M.
  • Aristides Capital's ten largest holdings make up 50% of its $488M portfolio in Q4 2024.
  • Aristides Capital opened 127 new positions and closed 62 in Q4 2024.
  • Aristides Capital's portfolio value rose 52% quarter-over-quarter to $488M.

Based on Aristides Capital's 13F filing for Q4 2024, filed 13 Feb 2025.